N@N

Keay Nakae Maintained (ALNY) at Strong Buy with Increased Target to $250 on, Aug 4th, 2022

Keay Nakae of Chardan Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $200 to $250 on, Aug 4th, 2022.

Keay has made no other calls on ALNY in the last 4 months.

There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 4 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• David Lebowitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $164 on, Friday, July 15th, 2022
• Olivia Brayer of "Cantor Fitzgerald" Initiated at Hold and Held Target at $175 on, Wednesday, July 13th, 2022
• Debjit Chattopadhyay of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, June 27th, 2022
• Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $98 on, Wednesday, June 15th, 2022

These are the ratings of the 2 analyists that currently disagree with Keay

---

• Myles Minter of "William Blair" Initiated at Buy on, Tuesday, June 7th, 2022
• Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $430 on, Monday, May 2nd, 2022

Contributing Sources

---